How much does retatrutide cost?
Retatrutide doesn’t have a price. It’s an investigational drug — Eli Lilly hasn’t set one, no US pharmacy can dispense it, and no insurance plan covers it. A price is something a manufacturer sets when a product is approved for sale, and retatrutide is still in Phase 3 trials.
That’s an unsatisfying answer to a search that gets typed 12,000 times a month, so here’s the useful version: what the numbers you’re seeing actually are, what a future price would plausibly look like, and what the drugs retatrutide would compete with cost right now.
Why there’s no price yet
Three separate things have to happen before retatrutide has a cost in any meaningful sense, and none of them has:
- Phase 3 has to finish and report. Lilly’s TRIUMPH program is still running. Results determine whether an application is even filed.
- The FDA has to review and approve it. That review is its own multi-month process, and approval isn’t guaranteed for any drug at any stage.
- Lilly has to set a launch price — and then insurers decide, plan by plan, whether to cover it and at what tier.
Only after all three does anyone know what someone actually pays. Until then, “retatrutide cost” is a question about the future, not the present.
What retatrutide is likely to cost if approved
The honest framing is a range, not a number. Lilly’s and Novo Nordisk’s current weight-management injectables carry list prices in roughly the $1,000–$1,350 per month band before insurance (⚠ verify current list prices — they move, and both makers have added lower-priced self-pay channels). A new drug with better trial numbers doesn’t usually launch below its predecessors, so that band is the sensible anchor.
What would actually determine your cost, if it gets that far:
- Which indications it’s approved for. Obesity-only approvals get worse coverage than diabetes approvals — the pattern that splits Zepbound from Mounjaro today.
- Whether a self-pay channel launches with it. Direct-to-consumer vial pricing has become the standard escape hatch for uninsured patients on this class.
- How fast formularies move. Coverage for new obesity drugs has historically trailed approval, sometimes by years.
- Savings-card terms. These almost always require commercial insurance that already covers the drug, which limits who they help.
None of that is settled, and a page that quotes you a confident 2027 monthly price is making it up.
What “retatrutide prices” online actually are
If a website quotes you a price for retatrutide, the price is the tell.
There’s a second cost people don’t price in: there’s nobody to go back to. With an approved drug, a bad lot is traceable, a pharmacy is licensed, a manufacturer is liable, and adverse events get reported to the FDA. With a grey-market vial, none of that machinery exists — you’re carrying the entire risk yourself, in exchange for a number on a checkout page. Where to buy retatrutide covers that landscape in full.
Will insurance cover retatrutide?
Not now — insurers don’t cover unapproved drugs, and there is no billing code, formulary tier, or prior-authorization pathway for one. Clinical trials are the only setting where anyone receives retatrutide today, and trial participants don’t pay for the study drug; the sponsor supplies it.
After a hypothetical approval, coverage becomes the real fight, and history isn’t encouraging: many commercial plans still exclude weight-loss medication as a category, and Medicare is barred from covering drugs prescribed solely for weight loss (⚠ policy in flux — proposals to change this surface regularly). A stronger drug doesn’t change a plan’s category exclusion.
What an approved alternative costs today
If cost is the reason you’re here, this is the part that’s actionable. These are drugs a licensed prescriber can start you on this week, at prices that actually exist.
- Tirzepatide (Zepbound / Mounjaro)
- ~$1,000–$1,090/mo list ⚠ verify — self-pay vial pricing and savings cards can cut this substantially
- Semaglutide (Wegovy / Ozempic)
- ~$1,000–$1,350/mo list ⚠ verify — coverage and savings programs drive most of the variance
- With commercial coverage
- often $25–$150/mo when the plan covers the indication; savings cards require commercial insurance
- Retatrutide
- no price exists investigational — not available at any price
This page is informational and is not medical advice. Retatrutide is an investigational drug that is not approved by the FDA and cannot be legally prescribed, sold, or purchased in the US. See our medical disclaimer.